Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use

Allergan is introducing Restasis (Ree-STAY-sis), a new cyclosporine emulsion for ophthalmic use.

Restasis is approved for patients with chronic dry eye disease...also called keratoconjunctivitis sicca.

Chronic dry eye disease is caused by chronic inflammation, aging, or autoimmune disorders such as Sjögren's syndrome.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote